Tumor necrosis factor ␣ (TNF␣) has been implicated in the pathogenesis of graft-versus-host disease (GVHD). In this study, serum levels of TNF␣ were assessed by ELISA in 243 sera samples from 40 patients who had undergone allogeneic bone marrow transplantation (BMT). Serum TNF␣ levels were measured before BMT and at different time points after BMT. The results were correlated with acute GVHD (aGVHD), infection and conditioning regimen. Serum TNF␣ levels were significantly higher in patients with grades II-IV aGVHD than in those with grade 0 or I aGVHD, but there was no clear correlation between serum TNF␣ and severity of aGVHD. Serum TNF␣ levels in infected patients were not statistically different from those in patients without infection. The conditioning regimen did not cause a significant rise in TNF␣ levels. These results indicate that TNF␣ may be useful for the diagnosis of aGVHD and for differentiating between aGVHD and other BMTrelated complications, such as infection. Leukemia (2001) 15, 1089-1091.
Introduction
Acute graft-versus-host disease (aGVHD) after allogeneic bone marrow transplantation (BMT) remains a potentially fatal complication involving the gut, liver and skin. 1 The diagnosis of aGVHD is mainly based on clinical evaluation because biopsies can rarely be obtained due to thrombocytopenia. The clinical symptoms of aGVHD often resemble those of organ toxicity, drug rash or infection. Confirmation of diagnosis is therefore difficult. Additional indicator parameters supporting the diagnosis of aGVHD would be of great clinical value for discriminating between symptoms of aGVHD and those of drug rash, infection or organ toxicity.
The role of donor T cell activation in aGVHD has been confirmed by experimental and clinical studies. Nowadays, there is increasing evidence for the additional involvement of cytokines, 2 especially tumor necrosis factor (TNF) [3] [4] [5] in aGVHD. In particular, antibodies against TNF␣ prevent aGVHD and intestinal graft-versus-host reaction in mice and humans. [6] [7] [8] We report our study of TNF␣ levels in 40 patients before and after allogeneic BMT to evaluate TNF␣ as a potential indicator to help establish the diagnosis of aGVHD and discriminate symptoms of aGVHD from those of organ toxicity and infection.
Patients and methods

Patients
This study included 40 patients who underwent BMT between March 1998 and September 1999 in our hospital. Among them, 35 patients received bone marrow from human leukocyte antigen (HLA)-identical sibling donors, two patients from HLA/MHC mismatched sibling donors, and the other three from HLA-matched unrelated volunteer donors. The median age of the patients was 33 years (range 15-45). Underlying diseases included acute lymphocytic leukemia (ALL, n = 4), acute myelocytic leukemia (AML, n = 18), and chronic myelocytic leukemia (CML, n = 18).
Serum samples
Serum samples were collected both before and after BMT. During conditioning regimen, a blood sample was obtained from each patient 6 to 9 days before transplantation. After BMT serum samples were collected every 7-14 days until day 100 or death, including one sample at the end of the conditioning regimen. All sera were stored at −80°C immediately after centrifugation until further use.
Conditioning
For all patients transplant conditioning regimen consisted of busulphan 4 mg/kg of the recipient's body weight per day × 3 days, cytosine Ara-C 2 g/m 2 , hydroxyurea 80 mg/kg body weight, cyclophosphamide 1.8 g/m 2 per day × 2 days, and methyl-lomustine 250 mg/m 2 . In two cases, antithymus globulin was added to this conditioning regimen.
Prophylaxis against aGVHD
Forty patients received cyclosporin A combined with methotrexate as GVHD prophylaxis. Cyclosporin A was given at 2.5 mg/kg body weight per day i.v. divided into two doses starting 1 day before transplantation. Methotrexate was given at 15 mg/m 2 i.v. on day 1 after transplantation and 10 mg/m 2 on days 3, 6 and 11. For the two patients receiving HLAmismatched bone marrow transplantation, in vitro T cell depletion was used as additional GVHD prophylaxis.
If aGVHD occurred, methotrexate, glucocorticoids, antithymus globulin and other immunosuppressive drugs were given. aGVHD was graded according to the criteria described by Thomas. 9 Determination of serum TNF␣ Serum TNF␣ level was determined by a highly specific and sensitive sandwich enzyme-linked immunosorbent assay (ELISA) 3,5,10 with a commercially available kit (sandwich ELISA TNF␣ test kit) containing monoclonal antibodies and standards. The TNF kit was produced by Beijing BiotingeTech, Beijing, China. With these monoclonal antibodies, dif-ferent subunits of human TNF␣ were detected. Ninety-six-well plates were coated with the coated monoclonal antibody 100 l/well for 48 h at 4°C. The wells were washed with phosphate-buffered saline containing 0.05% Tween-20. Then, 100 l of the serum samples and standards were added to the wells and incubated for 1 h at 37°C. A two-fold dilution of the standard ranged from 10 ng/ml to 78 pg/ml. After the wells were washed, 100 l HRP-labeled monoclonal antibody was pipetted into the wells, and the plate was incubated for 1 h at 37°C. The ELISA was developed with 0.5 mg/ml 2,2Ј-azinobis-(3-ethylbenzthiozoline 6-sulfonicacid) and 0.003% H 2 O 2 for 30 min at room temperature. The plates were read at 410 nm in a microplate reader. The sensitivity was 100 pg/ml. TNF␣ levels lower than 100 pg/ml were considered negative.
Infections
Infections included viral, bacterial and fungi. Infections were defined as temperature persistent higher than 38.5°C, with physical signs, etiology evidence (throat, phlegm cultivation, blood culture, CMV DNA in peripheral blood and urine by PCR, etc) or chest X-ray.
Statistical analysis
The results are reported as mean ± standard deviation. Statistical comparison between groups was performed using the unpaired Student's t-test. A level of P Ͻ 0.05 was considered statistically significant.
Results
Serum TNF␣ level and aGVHD
Grade 0-I aGVHD was seen in 28 of the 40 patients, grade II in five and grade III-IV in seven; of the 28 patients with grade 0-I aGVHD, 23 had negative TNF␣ levels. In the other five patients, TNF␣ levels increased temporarily after BMT to as high as 2.530 ng/ml. TNF␣ levels in four patients with grade II aGVHD and in all seven patients with grade III-IV aGVHD were persistently high during the periods of aGVHD; the highest levels were 4.897 ng/ml and 4.210 ng/ml, respectively. The mean serum levels of TNF␣ in patients with grades II and III-IV aGVHD were significantly higher than that of patients with grade 0-I aGVHD (P Ͻ 0.001); however, the clinical severity of aGVHD did not correlate with the serum TNF␣ level (Table 1) . We did not find a significant difference in TNF␣ level between patients with grade II and grade III-IV aGVHD (P = 0.1). In 11 of 12 patients with grade II-IV aGVHD, TNF␣ levels were negative before onset of aGVHD, increased significantly during the period of aGVHD, and gradually decreased as aGVHD resolved after effective treatment ( Table 2 ). In one patient with restricted skin rash grade II aGVHD, however, serum TNF␣ level was persistently negative.
TNF␣ and infection
To analyze the effects of infections on TNF␣ levels, the absence or presence of infection was recorded when each sample was taken. Table 3 shows the mean serum TNF␣ levels measured in the presence of 0-I, II and III-IV aGVHD and in the absence and presence of infection. Statistical analysis showed that TNF␣ was not significantly increased due to infections.
TNF␣ and conditioning regimen
TNF␣ levels in three patients increased at the end of the conditioning regimen. The patient with the highest level of TNF␣ (4.210 ng/ml) had superacute GVHD 1 week later and then grade II GVHD. However, the other two patients, with peak TNF␣ levels of 1.804 ng/ml and 1.848 ng/ml, showed no signs of aGVHD. We did not observe any correlation between TNF␣ level at the end of conditioning and aGVHD.
Discussion
In this study, we evaluated the potential for serum levels of TNF␣ to discriminate between the symptoms of aGVHD and organ toxicity or infection in patients who had undergone allogeneic BMT. Symptoms common to all three conditions include skin rash, diarrhea and elevated liver enzymes and bilirubin. We found that serum TNF␣ levels were higher in Table 3 TNF␣ levels of serum samples after bone marrow transplant with and without infections aGVHD
Without infection With infection P value grade n TNF␣ (ng/ml) n TNF␣ (ng/ml) patients with grade II-IV aGVHD than in those with grade 0-I aGVHD; however, there was no clear correlation between serum TNF␣ levels and severity of aGVHD. We also demonstrated that serum TNF␣ levels in patients with infection were not statistically different from those in patients without infection. These results indicated that increased serum levels of TNF␣ after allogeneic BMT may be helpful in establishing and supporting the diagnosis of aGVHD. Our results agree with those reported by Remberger et al, 4 but disagree with the report by Holler et al. 3 In the report by Holler, serum levels of TNF␣ were elevated not only in patients with aGVHD but also in patients with other complications, such as infections. Considering similar research design, size of patient subgroups and sensitivity of TNF␣ detection (100 pg/ml), we cannot provide a satisfactory explanation for the discrepancies in the findings. Regardless, our results indicate that measuring serum TNF␣ levels could be a means of differentiating between the diagnosis of aGVHD and other BMT-related complications such as infection.
One surprising finding of our study was that the serum level of TNF␣ at the end of conditioning in most of our patients was negative, including in those who later developed grade II-IV aGVHD. This finding means that serum levels of TNF␣ at the end of conditioning do not appear to be predictive for aGVHD. Furthermore, this result contrasts with that reported by Remberger et al. 4 In our study, patients were treated with a modified busulphan + cyclophosphamide conditioning regimen, which may partly explain the discrepancy in the finding. Because experimental and clinical data confirm that TNF␣ plays an important role in the pathogenesis of aGVHD, and chemotherapy and total body irradiation-induced tissue damage may pave the way for aGVHD, our finding may indicate our conditioning regimen is better than traditional conditioning regimens in terms of aGVHD induction.
In conclusion, increased serum levels of TNF␣ after allogeneic BMT may be helpful in establishing and supporting the diagnosis of aGVHD and in starting adequate treatment as early as possible. However, one should be careful in interpreting increased serum levels of TNF␣ in the absence of symptoms and signs of aGVHD; in that situation, serial monitoring of serum TNF␣ would be helpful.
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